These days pharma does r&d with the balance sheet through M&A and partnering deals that don't show up in the r&d line items
Drug prices are lower ex us bc marginal price is still greater than marginal cost. However if prices weren't high in US, EU and Japan than everywhere else, the drugs wouldn't be developed in the first place
you may not be thinking about market systems in the whole in each jurisdiction -- specifically the relationship of insurance and nation-wide health care monies, applied to the costs of medications to consumers, in non-US markets.
Still I’m sure there’s a solid scientific or medical reason why a year’s supply of something in Canada or Europe costs a fraction of a month’s supply in the States. I’m voting for “greed” and “systemic forces which allow it.” It sure as shit isn’t R&D...